BETA2026-07-012026-09-30BETA2026-09-30BETA2026-03-31BETA2026-04-012026-09-30BETA2026-07-012026-09-30in-capmkt:OtherExpenses1MemberBETA2026-04-012026-09-30in-capmkt:OtherExpenses1MemberBETA2026-09-30OtherNoncurrentFinancialAssetsDomain1BETA2026-09-30OtherNoncurrentAssetsDomain1BETA2026-09-30OtherCurrentFinancialAssetsDomain1BETA2026-09-30OtherCurrentAssetsDomain1BETA2026-09-30OtherNoncurrentLiabilitiesDomain1BETA2026-09-30OtherCurrentFinancialLiabilitiesDomain1BETA2026-09-30OtherCurrentLiabilitiesDomain1BETA2026-07-012026-09-30RelatedPartyTransactionDomain1BETA2026-06-30RelatedPartyTransactionDomain1BETA2026-09-30RelatedPartyTransactionDomain1BETA2026-07-012026-09-30RelatedPartyTransactionDomain2BETA2026-06-30RelatedPartyTransactionDomain2BETA2026-09-30RelatedPartyTransactionDomain2BETA2026-07-012026-09-30RelatedPartyTransactionDomain3BETA2026-06-30RelatedPartyTransactionDomain3BETA2026-09-30RelatedPartyTransactionDomain3BETA2026-07-012026-09-30RelatedPartyTransactionDomain4BETA2026-06-30RelatedPartyTransactionDomain4BETA2026-09-30RelatedPartyTransactionDomain4BETA2026-07-012026-09-30RelatedPartyTransactionDomain5BETA2026-06-30RelatedPartyTransactionDomain5BETA2026-09-30RelatedPartyTransactionDomain5BETA2026-07-012026-09-30RelatedPartyTransactionDomain6BETA2026-06-30RelatedPartyTransactionDomain6BETA2026-09-30RelatedPartyTransactionDomain6BETA2026-09-30Statement1BETA2026-07-012026-09-30Statement1BETA2026-09-30StatementDynamic1I1Statement1BETA2026-09-30StatementDynamic1I2Statement1BETA2026-09-30StatementDynamic1I3Statement1BETA2026-09-30StatementDynamic1I4Statement1BETA2026-09-30StatementDynamic1I5Statement1BETA2026-09-30StatementDynamic1I6Statement1BETA2026-09-30StatementDynamic1I7Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000BETANOTLISTEDINE351Y01019BETA DRUGS LIMITEDMain BoardEquity2026-04-012027-03-312026-10-222026-10-15INRLakhsQuarterlySecond quarterSingle segmentPHARMACEUTICAL2026-10-2209:00:002026-10-2211:05:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-05-15www.betadrugslimited.comtrue1falseNA2026-07-012026-09-30UnauditedStandalone580110000185890005986990003032660000-10616000940970006509000262740001294350005489650004973400004973400014040000-142500012615000037119000000037119000037119000111212000103.293.29003.293.291. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 22nd October, 2026. <br /> 2.The company is engaged in single business segment i.e. Pharmaceuticals. <br /> 3.Figures are regrouped/rearranged, wherever considered necessary. <br /> 2026-04-012026-09-30UnauditedStandalone11383680003726300011756310005633030000-1258700018766600022515000511240002344980001046519000129112000012911200035721000-306300032658000096454000000096454000096454000111212000108.848.84008.848.84Other Expenses129435000Other Expenses2344980006817080000866400007517080000242222000993930000172950001233730001902946000345276000063744400015010009800480000106297000172529000086600002079226000398217200011121200030666300003177842000317784200013136100000013136100015182000217940001683370008077800004644760004644760003979700058505100032706000182360006359930008043300003982172000Other Financial Assets242222000Other non-current assets123373000Other financial assets106297000Other Current assets8660000Other non-current liabilities21794000Other Financial liablities39797000Other current liabilities3270600022515000-31122000-9939000003068800000002126800002190000051123000000000000000000-272800012638400000-291590000-21518000757070000000000003171600006939670000314260000000000002654900000002915900000-75449900000158580800000000559070001143218000002251500000475982000-2028100000-2028100001184358000981548000Beta DrugsLimited******Adley Lab Limited******Wholly Owned SubsidiaryPurchase of goods or services160300000NA1603000002026-10-22160300000-122408000-153508000Beta Drugs Limited******Adley Lab Limited******Wholly Owned SubsidiaryInterest received4662000NA46620002026-10-224662000101585000105782000Loan0.09NAUnsecuredFor Business Development and expansion of operationsBeta Drugs Limited******Adley Formulations Private Limited******Wholly Owned SubsidiarySale of goods or services33251000NA332510002026-10-22332510007235600076417000Beta Drugs Limited******Adley Formulations Private Limited******Wholly Owned SubsidiaryPurchase of goods or services15385000NA153850002026-10-22153850009060000083994000Beta Drugs Limited******Adley Formulations Private Limited******Wholly Owned SubsidiaryInterest received2669000NA26690002026-10-2226690005816700060559000Loan0.09NAUnsecuredFor Business Development and expansion of operationsBeta Drugs Limited******BT Associates Private Limited******Wholly Owned SubsidiaryAny other transactionPayment of Building Rent1444000na14440002026-10-22144400043000373000217711000Preferential Issues2024-11-2511701000002026-09-30trueBrickwork Ratings India Private LimitedfalsefalsefalsefalseRajni BrarCompany Secretary and Compliance OfficerPanchkula2026-10-22Facility Upgradation of 100% Subsidiary - Adley Formualtions Pvt Ltd.NA80000002250000Facility Upgradation of 100% Subsidiary - Adley Lab Ltd.NA50000001350000R & D facilty (new setup)NA15000000950000Geographical Expansion it includes new registrations, audits, dossiers costs, bioequivalence studies cost.NA1000000000Capital Expenditure (Manufacturing- new setup)NA440000009520000Capital Investment (including capital acquisitions)NA2000000019940000General Corporate PurposeNA1500000013360000